S2 Appendix: Statistical Analysis Plan.

Version 1.0, 9 October 2019

The following document was lodged with the Research Ethics Committee of the Health Research

Authority on 9 October 2019, before analysis commenced in this study.

Baseline assessment

Eligibility criteria were assessed at recruitment. They will be reported in summary form i.e. pubertal

stage and phenotype of genitalia, bone age, and normality of karyotype, pelvic ultrasound and short

synacthen test (the latter two for birth-registered females only).

Outcomes

Outcomes at baseline and follow-up were assessed in four domains:

a. Puberty and growth

b. Medical safety

c. Bone health

d. Psychological function

Two outcomes were assessed only during or after treatment.

e. Treatment satisfaction

f. Decision made at the end of treatment.

The Table below lists the specific outcomes from each domain, along with their expected or

hypothesised change from baseline and the analytic plan for each outcome.

1

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
A. PUBERTY & GR	OWTH			
1.	Gonadotropins (LH, FSH; in both sexes),	At 6 and	The aim of GnRHa treatment was to suppress LH and	a. Categorical: Report of whether
Gonadotropins	testosterone (in birth-registered males) and	12	FSH production, leading to the 'turning off' of gonads	sex steroids and gonadotropins
and sex steroids	oestrogen (birth-registered females)	months	and therefore suppression of testosterone or	were suppressed at 6 to 12
		then	oestrogen (depending on birth registered sex).	months
		annually		b. Mean value and 95% CI for
			Hypothesis: that hormones will be suppressed to	hormones at 12, 24 and 36
			prepubertal levels by 6 to 12 months.	months
2. Growth	Height, weight and calculated BMI	6 monthly	Height: Height growth during puberty is dependent on	z-scores for height, weight and
		initially	the twin effects of sex steroids (oestrogen or	BMI calculated for age and sex at
		and	testosterone) and growth hormone. The pubertal	12, 24 and 36 months using the
		thereafter	growth spurt occurs around Tanner stage 2-3 in	UK 1990 growth reference.
		12-	females and stage 3-4 in males. GnRHa treatment is	Analysis will be restricted to
		monthly	expected to dramatically reduce height growth	calculation of means and 95%
			compared to adolescent peers who are growing	confidence intervals (95% CI) at
			rapidly. This will show as only small growth in height	each time point, and no statistical
			but a fall in height z-score (i.e. standard deviation	testing will be done
			score adjusted for age and sex).	

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
			Hypothesis: height velocity will be reduced to prepubertal levels, with a matching fall in height z-score.  Weight and BMI: No definitive hypotheses. We will examine weight and BMI standardized for age and sex	
			through use of weight and BMI z-score.	
3. Pubertal	Pubertal staging (Tanner staging) is conducted	Baseline	The aim of GnRHa treatment is to prevent further	Baseline: proportions in each
progress	by physical examination or by self-report, and reports the degree to which young people have	and end of follow-	progression in puberty during treatment. Young people will be categorised as stage 2 through 5 at	Tanner stage
	progressed from prepubertal (stage 1) to fully puberty (stage 5) in 3 areas for each birth	up	baseline and monitored for pubertal progression.	Follow-up: proportions with any pubertal progression or not
	registered sex.  a. genital and pubic hair stage and testicular volume in males;  b. Breast and pubic hair stage and menarcheal status in females.		Hypothesis: No pubertal progression	

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
	For analysis the three values for each birth			
	registered sex were combined into an overall			
	stage i.e. 2 through 5. This is common practice			
	in clinical research.			
B. MEDICAL SAFE	ТҮ			
1. Safety bloods	1. Liver & renal function	12-	Safety bloods were designed to assess impact on liver	Individual tests are not outcomes
	2. Full blood count	monthly.	and renal function, basal endocrinology and basic	of interest aside from overall
	3. Bone profile		haematology.	safety. Bloods were taken at
	4. Basal endocrinology	Liver and		regular intervals but for
	5. Vitamin D	renal	Hypotheses: No change in any measured parameters	parsimony will reported at 12, 24
		function		and 36 months. Reporting of
		also		outcomes will be categorical in
		assessed		terms of normality of each test,
		at 3m.		with numbers with identified
				abnormalities of any test. The
				reference norms for the
				laboratory where testing was
				done (UCLH) will be used to

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
				define normality. No statistical
				testing will be done.
2. Adverse	Patient report of adverse events from	At 6, 12,	Expected adverse effects were not specified in the	Presence or absence of reported
events	a. clinic visits	24, 36	Protocol. Any adverse events noted at clinic visits will	side-effects
	b. patient interviews	and 48m	be reported.	
	At each clinic visit, patients were routinely			
	asked about adverse events.		Note that formal semi-structured interviews at 6-12	
			months after commencement also sought information	
			on side-effects and these data will be contribute to	
			side-effect reporting.	
C. BONE				
HEALTH				
1. Bone mineral	DEXA scan report of bone mineral density in	Annually	There is a strong relationship between bone strength,	Change in continuous measures
density	lumbar spine (L1-4) and hip:		height and puberty. Normatively, BMC and BMD rise	of BMC, BMD and BMD HAZ at
	Primary outcomes in spine and hip:		during adolescence due to the action of sex steroids	12, 24 and 36 months.
	1. Bone mineral content (BMC)		on bone mineral accretion and because of height	
	2. Bone mineral density (BMD)		growth.	Formal statistical testing will be
	Secondary outcomes: calculated BMD z-score			restricted to change in BMC and
	for age & sex, regression-adjusted for change in		This will not occur if puberty is suppressed, as height	BMD as primary outcomes.
	height z-score (height adjusted z-score: HAZ)		does not increase and because bone mineral accretion	Means and 95% confidence

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
			is not promoted by sex steroid. The expectation is	intervals (95% CI) will be
			therefore that during GnRHa treatment bone strength	calculated for HAZ at each time
			as measured by BMC and BMD will not fall during	point.
			treatment – but that it will not increase as expected	
			from age and height growth. BMD z-scores for age	
			reflect population increases in bone mineral,	
			therefore z-scores will fall if puberty is suppressed,	
			although without any reduction in bone strength.	
			We hypothesise that there will be no change in	
			absolute BMD nor in BMC. However we expect that	
			BMD z-score will fall consistent with falls in height z-	
			score i.e. that HAZ will remain constant.	
D.				
PSYCHOLOGICA				
L FUNCTION				
1. Child	The Child Behavior Checklist (CBCL) (parent	At	Normative data show an increase in CBCL internalizing	We will use t- scores for
Behavior	report) and Youth Self Report (YSR) (self-report)	baseline	scores (i.e. psychological distress) with age in early	comparison with normative
Checklist (CBCL)	are measures of psychological functioning	and again	adolescence.[22] It is therefore likely that any	published data:

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
and Youth Self-	(aseba.org). Both provide continuous data/ t-	after	improvements in psychological function with	total problems score
Report (YSR)	scores for the total problem scale (a global	around 12	treatment are likely to result in smaller rises in	2. internalising subscale
	index of functioning across all subscales). They	months	distress with age, meaning that there will be no	score
	also provide continuous data/ t-scores on the	on	discernible change in psychological function over time	3. externalising subscale
	internalizing subscale (items which assess	treatment	in our cohort.	score
	anxious/depressed, withdrawn-depressed, and			Change in total problems score
	somatic complaints) and the externalizing		Previous data from the London service and	will be tested. Change in
	subscale (focusing on rule-breaking and		internationally show high rates of psychological	internalising and externalising t-
	aggressive behaviours). The CBCL is used for		distress in young people with GID.[42] Thus our	scores will be estimated by
	children aged 6 to 18 and consists of 113		sample is a group in whom distress begins at levels	calculating mean and 95% CI.
	questions. Both are scored on a three-point		higher than the general population, but who will also	
	Likert scale (0=absent, 1= occurs sometimes,		suffer from the normative increase in distress across	
	2=occurs often). The time frame for item		the study period.	
	responses is the past six months.			
			We therefore hypothesise there will be	
	Raw scores are converted for analysis to t-		1. no change in total problem t-scores	
	scores based upon broad age-ranges.		2. no change in externalizing or internalizing	
			subscale t-scores	
	Higher scores indicate greater morbidity.			

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
			This is consistent with a potential reduction in distress	
			due to treatment at a time when there is a	
			developmental rise in distress.	
2. Youth Self-	The YSR is the self-report version of the CBCL	Baseline	Normative data show rising YSR total problems scores	Change in total problems t-score
Report (YSR)	(see above). The YSR is suitable for children and	and	with age from age 11 to 16 years in healthy young	will be tested. Change in
	adolescents aged 11-18 years and consists of	follow-up	people from a range of different countries.[23]	internalising and externalising t-
	112 questions.			scores will be estimated by
			As above we hypothesize that there will be	calculating mean and 95% CI at
	Higher scores indicate greater morbidity.		1. no change in total problem t-scores	each time point. Change in total
			2. no change in z-scores for total problems	problems z-scores will be
	As per the CBCL, raw scores are converted to t-		3. no change in externalizing or internalizing	estimated by calculating mean
	scores for analysis. However t-scores are based		subscale scores	and 95% CI at each time point.
	upon broad age-ranges. To account for			
	normative change across our age-range, we will			
	also use international reference data[23] to			
	transform raw scores into z-scores for age and			
	sex.			
3. Self-harm	This will be assessed by 2 questions in each of		Self-harm rates in the general population in the UK	We will assess change by change
	the CBCL (parent report) and YSR (self-report).		and elsewhere increase markedly with age across	in self-harm/suicide items score.
			early to mid-adolescence, from very low in <10 year	This score combines all categories

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
	Item 18: I deliberately try to hurt or kill myself		olds to peak around age 16-17 years.[43-46] This is	of self-harm and suicidal ideation,
	(self-harm)		likely related to adolescent development, particularly	including intermediate and high
	Item 91. I think about killing myself (suicidal		cognitive development.	categories of risk. This will be
	ideation)			formally tested.
			Self-harm is highly prevalent in young people with	
	For each question in both CBCL and YSR the		GID, similar to rates in young people with a range of	
	responses are:		serious mental health problems.[34]	
	0=not true			
	1=somewhat or sometimes true		Thus our sample is a group in whom self-harm begins	
	2= very true or often true		at levels higher than the general population, but who	
			will also suffer from the normative increase in self-	
	We will use these items to calculate a self-		harm across the study period.	
	harm/suicide items score at each timepoint by			
	sum of the 2 items in each of the CBCL and YSR,		We hypothesise no change in self-harm across the	
	as published by other authors.[24, 25] This		study. This is consistent with a reduction in the	
	produces a scale from 0 to 4 for each question –		propensity to self-harm due to treatment at a time	
	with higher score indicating greater		when there is a developmental rise in self-harm.	
	suicidality/self-harm thoughts and behaviour.			

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
4. Teacher	The Teacher Report Form (TRF) is the third			Not assessed.
Report Form	element of the Achenbach ASEBA system,			
	asking teachers similar questions to the CBCL			
	(parents) and YSR (young person self-report).			
	Attempts to obtain TRF data on participants			
	were rarely successful as this relied on families			
	organising completion and return of			
	questionnaires. Sample size for the TRF are			
	insufficient to report, therefore data are not			
	available on this outcome.			
5. Children's	The Children's Global Assessment Scale (CGAS),		Hypothesis: improvement in CGAS score with	Change will be estimated by
Global	adapted from the Global Assessment Scale for		treatment.	calculating mean and 95% CI.
Assessment	adults, is a rating of functioning aimed at			
Scale	children and young people aged 6-17 years old.			
	The child or young person is given a single score			
	between 1 and 100, based on a clinician's			
	assessment of a range of aspects related to a			
	child's psychological and social functioning, with			
	the time period being the last month. The score			
	puts them in one of ten categories that range			

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
	from 'extremely impaired' (1-10) to 'doing very			
	well' (91-100).[29] The CGAS is a commonly			
	used measure in child and adolescent mental			
	health services in the UK.			
	Higher scores indicate better function.			
6. Kidscreen- 52	Separate young person and parent		As for other items, It is likely that many of the	Change in parent and child
	questionnaires each consist of 52 items which		Kidscreen subscale scores will reflect normative	subscales will be estimated by
	assess 'Health Related Quality of Life' (HRQoL)		reductions in wellbeing and rises in mental health	calculating means and 95% CI.
	across ten dimensions: physical well-being;		problems across early adolescence.	
	psychological well-being; moods and emotions;			
	self-perception; autonomy; relations with		Hypothesis: no change in sub-scales.	
	parents and home life; social support and peers;			
	school environment; social acceptance			
	(bullying); and financial resources. Items use			
	five-point Likert-style scales to assess either the			
	frequency (never-seldom-sometimes-often-			
	always) of certain behaviours/feelings or the			
	intensity of an attitude (not at all–slightly-			

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
	moderately-very-extremely). The measure was			
	developed for young people aged 8-18 years.			
	The recall period is one week.			
	The questionnaires provide scores in the form			
	of continuous t-scores for the 10 subscales. T-			
	scores are derived from a multinational			
	European sample.[27]			
	Lower scores indicate greater morbidity.			
7. Body Image	The BIS is a self-report measure used to assess		Young people with GID have significant dissatisfaction	Change in t-scores for main/total
Scale (BIS)	body image satisfaction/ dissatisfaction. The		with their bodies, particularly those sexually	scale and for the subscales
	questionnaire provides a total score in the form		dimorphic elements.[47]	(primary, neutral and secondary
	of continuous data/ a t-score for the main scale			sex characteristics) will be
	(sum of all subscales) as well as for three		GnRHa treatment does not change the body in terms	estimated by calculating mean
	subscales assessing 'primary', 'secondary' and		of becoming the desired gender. GnRHa treatment	and 95% CI. No formal statistical
	'neutral' characteristics separately.[28]		only stops further progression in puberty i.e. it stops	testing will be undertaken.
			further development of unwanted gender	
	The questionnaire is used for children and		characteristics. It is therefore unlikely that GnRHa	
	adolescents aged 12 years and over. The		treatment will result in significant reduction in body	

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
	measure consists of 30 body features which the		dissatisfaction.[13] Use of cross-sex hormones	
	respondent is asked to rate in terms of		appears to improve body dissatisfaction in those with	
	satisfaction on a five-point scale (1= very		GID[47].	
	satisfied, 2 = satisfied, 3= neutral, 4 =			
	dissatisfied, and 5 = very dissatisfied). The			
	measure provides three scores for 'primary',		Hypothesis: There will be no change in BIS scores with	
	'secondary' and 'neutral' characteristics. The		GnRHa treatment.	
	primary characteristics subscale describes			
	satisfaction/dissatisfaction with the penis,			
	scrotum, testicles, facial hair, body hair, and			
	breasts for assigned males, and vagina, clitoris,			
	ovaries-uterus, breasts, chest, facial hair, and			
	voice for assigned females. The secondary			
	characteristics subscale is comprised of hips,			
	figure, waist, arms, buttocks, biceps,			
	appearance, stature, muscles, weight, thighs,			
	and hair for both sexes. It also includes voice			
	and chest for assigned males and body hair for			
	assigned females. The 'neutral' subscale,			
	defined as 'neutral' as the authors considered			

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
	them unresponsive to hormonal interventions,			
	is comprised of nose, shoulders, chin, calves,			
	hands, Adam's apple, eyebrows, face, feet, and			
	height for both sexes.			
	Higher scores represent higher degrees of body			
	dissatisfaction.			
8. The Utrecht	The GDS is a self-report measure used to assess		As noted above, GnRHa treatment does not change	Change in t-scores for total scale
Gender	the intensity of Gender Dysphoria. The		the body but merely prevents further pubertal	will be estimated by calculating
Dysphoria Scale	questionnaire provides a total score in the form		changes. GnRHa treatment is therefore unlikely to	mean and 95% CI. No formal
(UGDS)	of continuous data/ a t-score for one main scale		affect feelings of gender dysphoria.	statistical testing will be
	only.			undertaken.
	The questionnaire is used for children and		Hypothesis: gender dysphoria does not change with	
	adolescents aged 12 years and over. The		GnRHa treatment	
	questionnaire consists of 12 statements and			
	answers are given on a five-point scale to			
	indicate to what extent one agrees or disagrees			
	(1= agree completely, 2 = agree somewhat, 3=			

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
	neutral, 4 = disagree somewhat, and 5 =			
	disagree completely). A maximum score of 60			
	can be obtained. There are two separate			
	versions of the UGDS for assigned males (UGDS-			
	M) and assigned females (UGDS-F)			
	Higher scores indicate greater morbidity.			
9. Social	The Social Responsiveness Scale (SRS) (school		Young people with GID have been described to have	Not applicable.
Responsiveness	form) is a quantitative measure of autistic traits		relatively high levels of autistic traits. This may affect	
Scale	and symptoms in 4–18 year olds. It includes 18		the natural history of and response to treatments for	
	items. A total score is produced.[59]		GID. It is unclear whether autistic traits would	
			influence response to GnRHa treatment.	
			The SRS is used here as a baseline assessment of	
			autistic traits and as a predictor of outcome and NOT	
			as an outcome measure itself. The SRS was assessed	
			only at baseline and not at follow-up as it was not	
			anticipated that scores would change.	

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
E. Satisfaction				
with treatment				
1. Satisfaction	Satisfaction with treatment was assessed in	6 and 12	No hypothesis appropriate. No baseline data	Descriptive proportions.
with treatment	semi-structured interviews 6-12 months after	months	available.	
	commencing treatment.	on		
		treatment		
2. Continuation	Whether young people and families wished to			Descriptive proportions
of treatment	continue on treatment was assessed at each	Each		
	clinic visit	clinic visit		
F. Decisions				
made at end of				
GnRHa				
treatment				
pathway				
	GnRHa treatment was only provided in the	After age	No hypothesis.	Descriptive proportions.
	absence of sex steroids until around 16 years.	16 years.		
	After age 16 years young people were eligible			
	to elect to start cross-sex hormones. Young			
	people made a decision at the end of the			

Outcome	Description and measurement	Timing	Expected or hypothesised change on GnRHa	How assessed for study
				outcomes
	GnRHa pathway to either cease GnRH (with the			
	result that their body resumes production of			
	sex steroids) or commence cross-sex hormones.			
	This is a binary decision, made after at least 12			
	months on GnRHa and after the young person's			
	16 <sup>th</sup> year.			

Analysis methods

The original protocol stated: "All the data will be recorded and the questionnaires scored.

Descriptive statistics including means and standard deviations will be reported as well as parametric and non-parametric tests as appropriate."

Due to the small sample size, analyses will be largely restricted to descriptive statistics and elementary statistical tests.

Outcomes will be reported at baseline and 12, 24 and 36 months. Outcomes at 48 months will not be reported due to very low numbers.

For categorical outcomes, simple descriptive statistics will be reported.

For continuous measures we will formally test change using paired t-tests for the significance of the before/after difference of the main scales as specified above. For other scales and subscales we will calculate means and 95% CI at baseline and follow-up, showing baseline mean for both the whole sample and for the sample with data at the follow-up point.

Predictors of outcome: There are multiple hypotheses that could be made about whether individual demographic, physical or psychological factors relate to differences in outcomes, either by confounding or potentially more causally. Our design and study size mean that exploration of such hypotheses is not possible without high risk of chance findings. We will restrict analysis of predictors of outcome to two factors, birth registered sex and pubertal stage at baseline. We will restrict analysis to three continuous outcomes measured at baseline and 12 months. These outcomes were chosen as key outcomes across physical and mental health:

- a. bone mineral density (BMD) in the lumbar spine
- b. YSR total t-score
- c. CGAS score

We will do this by linear regression of follow-up score on baseline score, adding each predictor separately to each model and considering the interaction of predictor with baseline score. If both

factors appear to predict outcome, we will include these in a multivariable model and use backwards stepwise selection to identify the best predictive model.

We note that the nature of the patient group and their data are both unusual and highly sensitive, so that publication of findings may potentially identify individuals, particularly given the small sample size. We will consult with data protection experts to ensure that personal data are not disclosed.

## **Dissemination and Outputs**

The findings of this study are of considerable public interest. They will first be published in a peer-reviewed international journal with the paper made open-access. They will be also presented at academic and practitioner meetings. In addition, the investigators will seek to share the findings more widely with patient groups and other stakeholders, using plain English.

The Tavistock will prepare a patient information sheet summarising findings for participants and families and circulate it to the participants and their GPs.

## **References for the Statistical Analysis Plan**

- 1. Skordis N, Butler G, de Vries MC, Main K, Hannema SE. ESPE and PES International Survey of Centers and Clinicians Delivering Specialist Care for Children and Adolescents with Gender Dysphoria. Hormone research in paediatrics 2018; 90(5): 326-31.
- 2. Chew D, Anderson J, Williams K, May T, Pang K. Hormonal Treatment in Young People With Gender Dysphoria: A Systematic Review. Pediatrics 2018; 141(4).
- 3. Cohen-Kettenis PT, Schagen SE, Steensma TD, de Vries AL, Delemarre-van de Waal HA. Puberty suppression in a gender-dysphoric adolescent: a 22-year follow-up. Arch Sex Behav 2011; 40(4): 843-7.
- 4. de Vries AL, Steensma TD, Doreleijers TA, Cohen-Kettenis PT. Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. J Sex Med 2011; 8(8): 2276-83.
- 5. Spack NP, Edwards-Leeper L, Feldman HA, et al. Children and adolescents with gender identity disorder referred to a pediatric medical center. Pediatrics 2012; 129(3): 418-25.
- 6. Meyer WJ, 3rd. Gender identity disorder: an emerging problem for pediatricians. Pediatrics 2012; 129(3): 571-3.
- 7. Hewitt JK, Paul C, Kasiannan P, Grover SR, Newman LK, Warne GL. Hormone treatment of gender identity disorder in a cohort of children and adolescents. Med J Aust 2012; 196(9): 578-81.
- 8. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94(9): 3132-54.
- 9. Olson J, Chan Y-M, Garofalo R, et al. Impact of Early Medical Treatment for Transgender Youth: Protocol for the Longitudinal, Observational Trans Youth Care Study. JMIR research protocols 2019; 8(7): e14434.
- 10. Khadr S, Clarke V, Wellings K, et al. Mental and sexual health outcomes following sexual assault in adolescents: a prospective cohort study. Lancet Child Adolesc Health 2018; 2(9): 654-65.
- de Graaf NM, Cohen-Kettenis PT, Carmichael P, et al. Psychological functioning in adolescents referred to specialist gender identity clinics across Europe: a clinical comparison study between four clinics. Eur Child Adolesc Psychiatry 2018; 27(7): 909-19.
- 12. Crijnen AA, Achenbach TM, Verhulst FC. Comparisons of problems reported by parents of children in 12 cultures: total problems, externalizing, and internalizing. J Am Acad Child Adolesc Psychiatry 1997; 36(9): 1269-77.

- 13. Verhulst FC, Achenbach TM, van der Ende J, et al. Comparisons of problems reported by youths from seven countries. Am J Psychiatry 2003; 160(8): 1479-85.
- 14. Aitken M, VanderLaan DP, Wasserman L, Stojanovski S, Zucker KJ. Self-Harm and Suicidality in Children Referred for Gender Dysphoria. J Am Acad Child Adolesc Psychiatry 2016; 55(6): 513-20.
- 15. Van Meter AR, Algorta GP, Youngstrom EA, et al. Assessing for suicidal behavior in youth using the Achenbach System of Empirically Based Assessment. Eur Child Adolesc Psychiatry 2018; 27(2): 159-69.
- 16. Nock MK, Green JG, Hwang I, et al. Prevalence, correlates, and treatment of lifetime suicidal behavior among adolescents: results from the National Comorbidity Survey Replication Adolescent Supplement. JAMA Psychiatry 2013; 70(3): 300-10.
- 17. Jung KY, Kim T, Hwang SY, et al. Deliberate Self-harm among Young People Begins to Increase at the Very Early Age: a Nationwide Study. Journal of Korean medical science 2018; 33(30): e191.
- 18. Morey Y, Mellon D, Dailami N, Verne J, Tapp A. Adolescent self-harm in the community: an update on prevalence using a self-report survey of adolescents aged 13-18 in England. J Public Health (Oxf) 2017; 39(1): 58-64.
- 19. Stallard P, Spears M, Montgomery AA, Phillips R, Sayal K. Self-harm in young adolescents (12-16 years): onset and short-term continuation in a community sample. BMC psychiatry 2013; 13: 328.
- 20. Zucker KJ. Adolescents with Gender Dysphoria: Reflections on Some Contemporary Clinical and Research Issues. Arch Sex Behav 2019; 48(7): 1983-92.
- 21. Shaffer D, Gould MS, Brasic J, et al. A children's global assessment scale (CGAS). Arch Gen Psychiatry 1983; 40(11): 1228-31.
- 22. Ravens-Sieberer U, Gosch A, Rajmil L, et al. The KIDSCREEN-52 quality of life measure for children and adolescents: psychometric results from a cross-cultural survey in 13 European countries. Value Health 2008; 11(4): 645-58.
- 23. Lindgren TW, Pauly IB. A body image scale for evaluating transsexuals. Arch Sex Behav 1975; 4(6): 639-56.
- 24. Becker I, Auer M, Barkmann C, et al. A Cross-Sectional Multicenter Study of Multidimensional Body Image in Adolescents and Adults with Gender Dysphoria Before and After Transition-Related Medical Interventions. Arch Sex Behav 2018; 47(8): 2335-47.
- 25. Constantino JN, Davis SA, Todd RD, et al. Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord 2003; 33(4): 427-33.